A high quality GLP1 pill: once-daily Orforglipron
We take a look at the most recent set of results from Orforglipron, the oral GLP1 from Eli Lilly
The name is hard to pronounce, but Orforglipron is a promising GLP1 Receptor Agonist under development by Eli Lilly which we first covered way back in September 2024, and most recently this summer:
Eli Lilly’s other new GLP1 - Orforglipron
Eli Lilly is developing new GLP1 drugs, and Orforglipron is one of them. It’s not easy to pronounce, but it is easy to take, and easy to produce.
GLP1.Guide Staff
Preliminary results from the latest trial of Orforglipron (ATTAIN-1) have landed:
We dive into the results of the study along with a comparison of Orforglipron to other GLP1s:
The rest of this article is no longer available for free – if you'd like to read the rest of our analysis, check us out on Substack:
